What is Chardan Capital's Forecast for PRQR FY2024 Earnings?

ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Equities researchers at Chardan Capital decreased their FY2024 earnings estimates for ProQR Therapeutics in a research report issued to clients and investors on Sunday, November 10th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will earn ($0.31) per share for the year, down from their previous forecast of ($0.28). The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.34) per share. Chardan Capital also issued estimates for ProQR Therapeutics' FY2025 earnings at ($0.34) EPS.

A number of other brokerages also recently issued reports on PRQR. Raymond James raised ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their price objective for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. HC Wainwright boosted their price target on ProQR Therapeutics from $5.00 to $10.00 and gave the company a "buy" rating in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $7.13.

ProQR Therapeutics Stock Down 0.5 %

PRQR traded down $0.02 during trading on Wednesday, reaching $3.96. 1,297,920 shares of the stock traded hands, compared to its average volume of 525,825. The stock's 50-day moving average is $2.59 and its 200 day moving average is $2.13. ProQR Therapeutics has a 12 month low of $1.18 and a 12 month high of $4.62. The stock has a market capitalization of $323.45 million, a PE ratio of -12.38 and a beta of 0.26.

Institutional Investors Weigh In On ProQR Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. EP Wealth Advisors LLC acquired a new stake in ProQR Therapeutics in the 1st quarter valued at $26,000. Acadian Asset Management LLC bought a new stake in shares of ProQR Therapeutics during the first quarter worth about $56,000. BNP Paribas Financial Markets lifted its position in ProQR Therapeutics by 120.1% in the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company's stock valued at $80,000 after acquiring an additional 19,100 shares in the last quarter. OneDigital Investment Advisors LLC increased its holdings in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 15,550 shares in the last quarter. Finally, Ikarian Capital LLC raised its stake in shares of ProQR Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company's stock worth $1,098,000 after purchasing an additional 10,958 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company's stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).